On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN)’s shares declined -6.00% to $490.67.
Regeneron Pharmaceuticals, Inc. (REGN) and The Experimental Therapeutics Institute (ETI) at the Icahn School of Medicine at Mount Sinai recently declared that they have reached a contract with the aim of accelerating the discovery of fully human antibodies directed against therapeutic targets being researched by Mount Sinai investigators.
Regeneron will provide the ETI with access to VelocImmune® technology and potential financial support to use the company’s proprietary antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease. ETI will undertake preclinical research, and Regeneron has an exclusive option to negotiate a license to the antibody for future clinical development and commercialization.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide.
Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s shares dropped -6.40% to $6.38.
Sangamo BioSciences, Inc. (SGMO), a leader in therapeutic genome editing, declared unanimous approval by the National Institutes of Health’s Recombinant DNA Advisory Committee (RAC) of a Phase 1 study protocol for a ZFP Therapeutic as a potential curative therapy for hemophilia B. The Factor IX program will be the first clinical study of in vivo genome editing and the first therapeutic application of Sangamo’s In Vivo Protein Replacement Platform (IVPRP).
Sangamo anticipates to file an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) by the end of 2015 and, pending FDA clearance, plans to initiate a Phase 1 clinical trial in 2016. The Company recently re-attained all of its hemophilia assets from Shire plc as a result of the amendment to the companies’ 2012 partnership and license agreement.
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs.
At the end of Friday’s trade, Pioneer Natural Resources (NYSE:PXD)‘s shares dipped -0.68% to $122.34.
Pioneer Natural Resources Company (PXD) declared that Tim Dove, President and Chief Operating Officer, will present at The Johnson Rice Energy Conference on Tuesday, September 29, 2015 at 10:00 a.m. Central Time.
Pioneer Natural Resources Company engages in the exploration and production of oil and gas in the United States. The company produces and sells oil, natural gas liquids (NGLs), and gas.
Envestnet Inc (NYSE:ENV), ended its Friday’s trading session with 0.46% gain, and closed at $32.66.
BizEquity, the world’s leading online provider of business valuation knowledge and big data, recently declares that it has reached a contract to provide a unique benefit to clients of Envestnet, Inc. (ENV), a leading provider of unified wealth administration technology and services to investment advisors.
The opportunity will provide the more than 42,000 financial advisors that Envestnet empowers with a one-month free trial of BizEquity’s Advisor Office service, enabling them to enhance their service offerings and boost their prospecting capabilities. This special one-time offer will be accessible between now and September 30, 2015 and will run until December 31, 2015. BizEquity will be hosting a webinar on September 30th from 11:00 – 11:45 eastern time, to demo their technology and talk about the offer. For more information on the webinar please contact: Mary Jean Swiggard at [email protected].
Envestnet, Inc., together with its auxiliaries, provides wealth administration software and services to independent financial advisors and financial institutions in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.